Restart Life Sciences Management

Management criteria checks 1/4

Restart Life Sciences' CEO is Steve Loutskou, appointed in Oct 2024, has a tenure of less than a year. directly owns 3.11% of the company’s shares, worth €25.36K. The average tenure of the management team and the board of directors is 1.8 years and 3.3 years respectively.

Key information

Steve Loutskou

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	3.1%
Management average tenure	1.8yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO

Steve Loutskou

less than a year

Tenure

Mr. Steve Loutskou is President and Chief Executive Officer of Restart Life Sciences Corp. (formerly known as Nova Mentis Life Science Corp.) from October 22, 2024. He is Director of Restart Life Sciences...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rebecca Hudson	Chief Financial Officer	2.9yrs	CA$72.00k	1.17% € 9.5k
Derek Lloyd Ivany	Executive Chairman	1.8yrs	no data	2.4% € 19.6k
Steve Loutskou	President	less than a year	no data	3.11% € 25.4k
Aylia Mohammadi	President & Chief Scientific Officer of Nova Mentis Biotech Corp.	no data	CA$36.00k	no data
Kelly Pladson	Corporate Secretary	no data	no data	no data

1.8yrs

Average Tenure

41yo

Average Age

Experienced Management: HN3's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Derek Lloyd Ivany	Executive Chairman	1.8yrs	no data	2.4% € 19.6k
Steve Loutskou	President	less than a year	no data	3.11% € 25.4k
Marvin Hausman	Chairman of Scientific Advisory Board	3.9yrs	no data	no data
Georg Hochwimmer	Director	less than a year	no data	no data
Kyle Ambert	Member of Scientific Advisory Board	3.8yrs	no data	no data
Julia Perederiy	Member of Scientific Advisory Board	3.8yrs	no data	no data
Gary Harlem	Member of Scientific Advisory Board	3.8yrs	no data	no data
John Molinaro	Member of Scientific Advisory Board	2.8yrs	no data	no data
Viviana Trezza	Member of Scientific Advisory Board	no data	no data	no data

3.3yrs

Average Tenure

55yo

Average Age

Experienced Board: HN3's board of directors are considered experienced (3.3 years average tenure).

Restart Life Sciences Management

Management criteria checks 1/4

Key information

Recent management updates

Nova Mentis Life Science Corp Announces Chief Executive Officer Changes

Nova Mentis Life Science Corp., Annual General Meeting, Dec 03, 2024

Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director

Nova Mentis Life Science Corp., Annual General Meeting, Dec 29, 2023

Nova Mentis Life Science Corp. Announces Board Changes

Less than half of directors are independent

Recent updates

Nova Mentis Life Science Corp Announces Chief Executive Officer Changes

Nova Mentis Life Science Corp., Annual General Meeting, Dec 03, 2024

Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director

Nova Mentis Life Science Corp., Annual General Meeting, Dec 29, 2023

Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Nova Mentis Life Science Corp. Announces Board Changes

Nova Mentis Receives Health Canada Approval for First-Of-its-Kind Psilocybin Clinical Trial

Less than half of directors are independent

Nova Mentis Life Science Corp., Annual General Meeting, Dec 15, 2022

Nova Mentis Life Science Corp. Produces 1.5 mg Psilocybin Microdose Capsules

Nova Mentis Life Science Corp. Completes Production of Psilocybin Microdose Capsules

Nova Mentis Life Science Corp. Receives Controlled Substances Export Approval From The U.S. DEA for the Proprietary Psilocybin Drug NM 1001

Nova Mentis Life Science Corp. Appoints John Molinaro to its Scientific Advisory Board

Nova Mentis Life Science Corp Receives Approved Health Canada Importation Permit

Full year 2021 earnings released: CA$0.024 loss per share (vs CA$0.45 loss in FY 2020)

Less than half of directors are independent

Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study

Nova Mentis Completes Oral Microdose Psilocybin Preclinical Study

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Nova Mentis Life Science Corp. Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

First half 2021 earnings released: CA$0.009 loss per share (vs CA$0.20 loss in 1H 2020)

Nova Mentis Life Science Corp. Receives Canadian Approval for its North American Autism Clinical Study

Nova Mentis Life Science Corp. Launches Autism Clinical Study

Nova Mentis Life Science Corp. Announces the Launch of Its Us-Based Observational Study Nm- 101

Nova Mentis Life Science Corp. Receives Approval for Its First Clinical Program in Autism Spectrum Disorder

Nova Mentis Life Science Corp. Expands Pre-Clinical Development Pipeline and Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

Nova Mentis Life Science Corp. Appoints Gary R. Harlem to its Scientific Advisory Board

Nova Mentis Life Science Corp. Approves for Shipment to Italy

Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study

Nova Mentis Life Science Corp. Appoints Julia V. Perederiy, Phd to Its Scientific Advisory Board

Nova Mentis Life Science Corp Appoints Kyle H. Ambert as Scientific Advisory Board

Nova Mentis Life Science Corp. Announces That It Has Added Two Additional Psychedelic Compounds to Its Drug Portfolio

New 90-day high: €0.23

Nova Mentis Life Science Corp. Appoints Marvin S. Hausman as Chairman of Scientific Advisory Board

Nova Mentis Life Science Corp. Appoints Marvin S. Hausman MD as Chairman of Nova’S Scientific Advisory Board and Amalco’s Chief Medical Officer

Nova Mentis Life Science Corp. Announces Executive Changes

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age